Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Correlation between mutations in liaFSR of enterococcus faecium and MIC of daptomycin: Revisiting daptomycin breakpoints
Indexado
WoS WOS:000306826300039
Scopus SCOPUS_ID:84864390248
DOI 10.1128/AAC.00509-12
Año 2012
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Mutations in liaFSR, a three-component regulatory system controlling cell-envelope stress response, were recently linked with the emergence of daptomycin (DAP) resistance in enterococci. Our previous work showed that a liaF mutation increased the DAP MIC of a vancomycin-resistant Enterococcus faecalis strain from 1 to 3 mu g/ml (the DAP breakpoint is 4 mu g/ml), suggesting that mutations in the liaFSR system could be a pivotal initial event in the development of DAP resistance. With the hypothesis that clinical enterococcal isolates with DAP MICs between 3 and 4 mu g/ml might harbor mutations in liaFSR, we studied 38 Enterococcus faecium bloodstream isolates, of which 8 had DAP MICs between 3 and 4 mu g/ml by Etest in Mueller-Hinton agar. Interestingly, 6 of these 8 isolates had predicted amino acid changes in the LiaFSR system. Moreover, we previously showed that among 6 DAP-resistant E. faecium isolates (MICs of >4 mu g/ml), 5 had mutations in liaFSR. In contrast, none of 16 E. faecium isolates with a DAP MIC of <= 2 mu g/ml harbored mutations in this system (P < 0.0001). All but one isolate with liaFSR changes exhibited DAP MICs of >= 16 mu g/ml by Etest using brain heart infusion agar (BHIA), a medium that better supports enterococcal growth. Our findings provide a strong association between DAP MICs within the upper susceptibility range and mutations in the liaFSR system. Concomitant susceptibility testing on BHIA may be useful for identifying these E. faecium first-step mutants. Our results also suggest that the current DAP breakpoint for E. faecium may need to be reevaluated.

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Pharmacology & Pharmacy
Microbiology
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 MUNITA-SEPULVEDA, JOSE MANUEL Hombre Univ Texas Med Sch Houston - Estados Unidos
Universidad del Desarrollo - Chile
University of Texas Medical School at Houston - Estados Unidos
Clínica Alemana - Chile
2 Panesso, Diana Mujer Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia
University of Texas Medical School at Houston - Estados Unidos
Universidad El Bosque - Colombia
3 Diaz, Lorena Mujer Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia
University of Texas Medical School at Houston - Estados Unidos
Universidad El Bosque - Colombia
4 Tran, Truc T. Mujer Univ Texas Med Sch Houston - Estados Unidos
UNIV HOUSTON - Estados Unidos
University of Texas Medical School at Houston - Estados Unidos
University of Houston - Estados Unidos
5 Reyes, Jinnethe - Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia
University of Texas Medical School at Houston - Estados Unidos
Universidad El Bosque - Colombia
6 Wanger, Audrey Mujer Univ Texas Med Sch,Houston - Estados Unidos
University of Texas Medical School at Houston - Estados Unidos
Univ Texas Med Sch Houston - Estados Unidos
7 Murray, Barbara Mujer Ctr Study Emerging & Reemerging Pathogens - Estados Unidos
Univ Texas Med Sch,Houston - Estados Unidos
Univ Texas Med Sch Houston - Estados Unidos
Center for the Study of Emerging and Reemerging Pathogens - Estados Unidos
University of Texas Medical School at Houston - Estados Unidos
8 Arias, Cesar A. Hombre Univ Texas Med Sch Houston - Estados Unidos
Ctr Study Emerging & Reemerging Pathogens - Estados Unidos
Univ El Bosque - Colombia
University of Texas Medical School at Houston - Estados Unidos
Center for the Study of Emerging and Reemerging Pathogens - Estados Unidos
Universidad El Bosque - Colombia

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Origen de Citas Identificadas



Muestra la distribución de países cuyos autores citan a la publicación consultada.

Citas identificadas: Las citas provienen de documentos incluidos en la base de datos de DATACIENCIA

Citas Identificadas: 17.05 %
Citas No-identificadas: 82.95 %

Muestra la distribución de instituciones nacionales o extranjeras cuyos autores citan a la publicación consultada.

Citas identificadas: Las citas provienen de documentos incluidos en la base de datos de DATACIENCIA

Citas Identificadas: 17.05 %
Citas No-identificadas: 82.95 %

Financiamiento



Fuente
NIH
National Institute of Allergy and Infectious Diseases
Johnson Johnson
Pfizer, Inc.
Astellas
Cubist
NIH from the National Institute of Allergy and Infectious Diseases (NIAID)
Palumed
Intercell
Forrest Pharmaceuticals

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
Cesar A. Arias has received lecture fees, research support, and consulting fees from Pfizer, Inc., and Cubist and research support from Forrest Pharmaceuticals and has served as speaker for Novartis. Barbara E. Murray received grant support from Johnson & Johnson, Astellas, Palumed, Intercell, and Cubist, and has served as consultant for Astellas (Theravance), Cubist, Targanta Therapeutics (now owned by The Medicines Company), Pfizer, The Medicines Company, Rib-X, and Durata Therapeutics.

Muestra la fuente de financiamiento declarada en la publicación.